vs

Side-by-side financial comparison of TechTarget, Inc. (TTGT) and GeneDx Holdings Corp. (WGS). Click either name above to swap in a different company.

TechTarget, Inc. is the larger business by last-quarter revenue ($140.7M vs $121.0M, roughly 1.2× GeneDx Holdings Corp.). TechTarget, Inc. runs the higher net margin — -6.7% vs -14.6%, a 7.9% gap on every dollar of revenue. TechTarget, Inc. produced more free cash flow last quarter ($11.6M vs $-7.4M).

TechTarget, Inc. is an American company that offers data-driven marketing services to business-to-business technology vendors.

GeneDx is a genetic testing company that was founded in 2000 by two scientists from the National Institutes of Health (NIH), Sherri Bale and John Compton. They started the company to provide clinical diagnostic services for patients and families with rare and ultra-rare disorders, for which no such commercial testing was available at the time. The company started in the Technology Development Center, a biotech incubator supported by the state of Maryland and Montgomery County, MD. In 2006, Bi...

TTGT vs WGS — Head-to-Head

Bigger by revenue
TTGT
TTGT
1.2× larger
TTGT
$140.7M
$121.0M
WGS
Higher net margin
TTGT
TTGT
7.9% more per $
TTGT
-6.7%
-14.6%
WGS
More free cash flow
TTGT
TTGT
$19.0M more FCF
TTGT
$11.6M
$-7.4M
WGS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
TTGT
TTGT
WGS
WGS
Revenue
$140.7M
$121.0M
Net Profit
$-9.5M
$-17.7M
Gross Margin
63.8%
69.6%
Operating Margin
-10.5%
-11.8%
Net Margin
-6.7%
-14.6%
Revenue YoY
26.5%
Net Profit YoY
-424.9%
EPS (diluted)
$-0.09
$-0.59

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TTGT
TTGT
WGS
WGS
Q4 25
$140.7M
$121.0M
Q3 25
$122.3M
$116.7M
Q2 25
$119.9M
$102.7M
Q1 25
$103.9M
$87.1M
Q4 24
$95.6M
Q3 24
$62.9M
$76.9M
Q2 24
$70.5M
Q1 24
$62.4M
Net Profit
TTGT
TTGT
WGS
WGS
Q4 25
$-9.5M
$-17.7M
Q3 25
$-76.8M
$-7.6M
Q2 25
$-398.7M
$10.8M
Q1 25
$-523.4M
$-6.5M
Q4 24
$5.4M
Q3 24
$-17.4M
$-8.3M
Q2 24
$-29.2M
Q1 24
$-20.2M
Gross Margin
TTGT
TTGT
WGS
WGS
Q4 25
63.8%
69.6%
Q3 25
61.3%
72.4%
Q2 25
57.3%
69.0%
Q1 25
57.5%
67.1%
Q4 24
69.2%
Q3 24
62.1%
62.2%
Q2 24
60.9%
Q1 24
59.9%
Operating Margin
TTGT
TTGT
WGS
WGS
Q4 25
-10.5%
-11.8%
Q3 25
-88.2%
-2.8%
Q2 25
-342.1%
8.7%
Q1 25
-474.5%
-5.2%
Q4 24
9.2%
Q3 24
-22.9%
-10.1%
Q2 24
-15.0%
Q1 24
-21.9%
Net Margin
TTGT
TTGT
WGS
WGS
Q4 25
-6.7%
-14.6%
Q3 25
-62.8%
-6.5%
Q2 25
-332.4%
10.5%
Q1 25
-503.8%
-7.5%
Q4 24
5.7%
Q3 24
-27.7%
-10.8%
Q2 24
-41.4%
Q1 24
-32.4%
EPS (diluted)
TTGT
TTGT
WGS
WGS
Q4 25
$-0.09
$-0.59
Q3 25
$-1.07
$-0.27
Q2 25
$-5.58
$0.36
Q1 25
$-7.32
$-0.23
Q4 24
$0.25
Q3 24
$-0.42
$-0.31
Q2 24
$-1.10
Q1 24
$-0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TTGT
TTGT
WGS
WGS
Cash + ST InvestmentsLiquidity on hand
$40.6M
$171.3M
Total DebtLower is stronger
$54.5M
Stockholders' EquityBook value
$594.6M
$308.2M
Total Assets
$937.3M
$523.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TTGT
TTGT
WGS
WGS
Q4 25
$40.6M
$171.3M
Q3 25
$46.3M
$155.1M
Q2 25
$61.7M
$134.6M
Q1 25
$78.7M
$159.2M
Q4 24
$141.2M
Q3 24
$116.5M
Q2 24
$106.9M
Q1 24
$112.9M
Total Debt
TTGT
TTGT
WGS
WGS
Q4 25
$54.5M
Q3 25
$54.8M
Q2 25
$55.1M
Q1 25
$55.5M
Q4 24
$55.8M
Q3 24
$56.1M
Q2 24
$56.3M
Q1 24
$56.3M
Stockholders' Equity
TTGT
TTGT
WGS
WGS
Q4 25
$594.6M
$308.2M
Q3 25
$597.9M
$292.3M
Q2 25
$668.7M
$277.1M
Q1 25
$1.1B
$257.4M
Q4 24
$245.2M
Q3 24
$134.2M
$204.5M
Q2 24
$194.0M
Q1 24
$207.2M
Total Assets
TTGT
TTGT
WGS
WGS
Q4 25
$937.3M
$523.7M
Q3 25
$987.4M
$493.9M
Q2 25
$1.1B
$463.9M
Q1 25
$1.5B
$446.4M
Q4 24
$419.4M
Q3 24
$0
$408.8M
Q2 24
$389.1M
Q1 24
$394.5M
Debt / Equity
TTGT
TTGT
WGS
WGS
Q4 25
0.18×
Q3 25
0.19×
Q2 25
0.20×
Q1 25
0.22×
Q4 24
0.23×
Q3 24
0.27×
Q2 24
0.29×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TTGT
TTGT
WGS
WGS
Operating Cash FlowLast quarter
$11.8M
$-3.1M
Free Cash FlowOCF − Capex
$11.6M
$-7.4M
FCF MarginFCF / Revenue
8.2%
-6.1%
Capex IntensityCapex / Revenue
0.1%
3.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$15.9M
$14.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TTGT
TTGT
WGS
WGS
Q4 25
$11.8M
$-3.1M
Q3 25
$-9.1M
$15.8M
Q2 25
$1.5M
$10.4M
Q1 25
$12.2M
$10.2M
Q4 24
$-3.2M
Q3 24
$-4.4M
Q2 24
$-4.5M
Q1 24
$-16.4M
Free Cash Flow
TTGT
TTGT
WGS
WGS
Q4 25
$11.6M
$-7.4M
Q3 25
$-9.3M
$9.6M
Q2 25
$1.4M
$8.1M
Q1 25
$12.2M
$4.1M
Q4 24
$-6.2M
Q3 24
$-5.0M
Q2 24
$-5.9M
Q1 24
$-16.9M
FCF Margin
TTGT
TTGT
WGS
WGS
Q4 25
8.2%
-6.1%
Q3 25
-7.6%
8.2%
Q2 25
1.2%
7.8%
Q1 25
11.7%
4.7%
Q4 24
-6.5%
Q3 24
-6.6%
Q2 24
-8.3%
Q1 24
-27.0%
Capex Intensity
TTGT
TTGT
WGS
WGS
Q4 25
0.1%
3.6%
Q3 25
0.1%
5.3%
Q2 25
0.0%
2.3%
Q1 25
0.0%
7.0%
Q4 24
3.2%
Q3 24
0.8%
Q2 24
1.9%
Q1 24
0.7%
Cash Conversion
TTGT
TTGT
WGS
WGS
Q4 25
Q3 25
Q2 25
0.96×
Q1 25
Q4 24
-0.59×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TTGT
TTGT

Segment breakdown not available.

WGS
WGS

Diagnostic Test Third Party Insurance$101.1M84%
Diagnostic Test Institutional Customers$15.5M13%
Other$3.4M3%

Related Comparisons